Furthermore, utilizing selective CTSS inhibitor, LY 3000328, has been shown to ameliorate neuroinflammation response, decrease activation of CX3CL1‐CX3CR1 axis and JAK2‐STAT3 pathway, and rescue AD‐related phenotypes in APP/PS1 transgenic mice. This evidence concerns the gene APP and Alzheimer disease.